XORTX Therapeutics (XRTX) Change in Accured Expenses (2020 - 2026)
XORTX Therapeutics (XRTX) posted Change in Accured Expenses of -$33529.0 for Q1 2026, down 527.94% on a QoQ basis from $7835.0 in Q4 2025, and down 1813.76% year-over-year from $1956.5 in Q1 2025.
XORTX Therapeutics (XRTX) Change in Accured Expenses (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$33529.0 for Q1 2026.
- Quarterly Change in Accured Expenses fell 1813.76% year-over-year to -$33529.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131026.0 (down 78.47% YoY) and the FY2025 annual result came in at $162803.0, down 21.79% from the prior year.
- Change in Accured Expenses was -$33529.0 for Q1 2026 at XORTX Therapeutics, down from $7835.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $438831.5 in Q2 2022 and bottomed at -$402068.0 in Q1 2024.
- A 5-year average of $64439.5 and a median of $78658.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 1367.11% — and 2026, when it plunged 1813.76%.
- XORTX Therapeutics' Change in Accured Expenses stood at -$306384.4 in 2022, then surged by 51.68% to -$148039.0 in 2023, then jumped by 145.76% to $67736.0 in 2024, then tumbled by 88.43% to $7835.0 in 2025, then tumbled by 527.94% to -$33529.0 in 2026.
- Business Quant data shows XRTX's Change in Accured Expenses at -$33529.0 in Q1 2026, $7835.0 in Q4 2025, and $67145.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | -33,529.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,529.00 |
| Mar 31, 2026 | -33,529.00 |
| Dec 31, 2025 | 7,835.00 |
| Dec 31, 2025 | 7,835.00 |
| Sep 30, 2025 | 67,145.00 |
| Sep 30, 2025 | 67,145.00 |
| Jun 30, 2025 | 89,575.00 |
| Jun 30, 2025 | 89,575.00 |
| Mar 31, 2025 | -1,752.00 |
| Mar 31, 2025 | -1,752.00 |
| Dec 31, 2024 | 67,736.00 |
| Dec 31, 2024 | 67,736.00 |
| Sep 30, 2024 | 110,754.00 |
| Sep 30, 2024 | 110,754.00 |
| Jun 30, 2024 | 431,744.00 |
| Jun 30, 2024 | 431,744.00 |
| Mar 31, 2024 | -402,068.00 |
| Mar 31, 2024 | -402,068.00 |
| Dec 31, 2023 | -148,039.00 |
| Dec 31, 2023 | -148,039.00 |